Alzheimer Disease Clinical Trial
Official title:
Effects of Exercise and Rivastigmine on Quality of Life of Alzheimer's Disease Patients
The purpose of this study is to determine whether a exercise program when combined with
rivastigmine (Exelon patch) drug treatment compared with rivastigmine drug treatment alone
would improve quality of life, ability to perform activities of daily living (ADL) and
cognition in patients with Alzheimer's disease.
Hypothesis:
Ho: Rivastigmine drug treatment combined with exercise is not superior to rivastigmine drug
treatment to improve quality of life of Alzheimer's disease patients.
H1: Rivastigmine drug treatment combined with exercise is superior to rivastigmine drug
treatment to improve quality of life of Alzheimer's disease patients, with an expectative of
15% of improvement in the quality of life scale measurement
After screening and informed consent, that will be collected demographical data from
patient. Another researcher will evaluate the cognition, through MMSE; the activities of
daily living, through Activities of Daily Living Questionnaire of Alzheimer disease; patient
and caregiver's quality of life through Quality of life scale in Alzheimer's disease
(QOL-AD); functional mobility, through Time Up and Go test.
Afterwards, the pharmacist will give the medicine, orientations about its administration and
clarify possible doubts. Therapy will begin with the small patch of 5 mg/24 h and, if well
tolerated, the dose will be increased to the 10 mg/24 h patch.
The patients will be randomly assigned, through a computer program list, to exercise or
control group. The patient and caregiver exercise group will receive information about the
two-day/week exercise program at physiotherapy ambulatory. Monthly, all patients and
caregiver will be clinically reevaluated during six months.
The forty minutes exercise program will include aerobic, strength, flexibility and balance
training, organize in the follow sequence:
- Ten minutes of global stretching (shoulder girdle, upper limbs, lower limbs and trunk)
along the beginning and final of the session. Each stretch posture will last 30 seconds.
Alternation of A and B sessions, lasting 30 minutes:
- Session A: Aerobic training on treadmill. Progression of 10 to 30 minutes of continuous
aerobic activity
- Session B: - Resisted kinesiotherapy (strength training) with use of weights to be
attached around the ankles and wrist of initially 1 Ib. The physiotherapist will
evaluate if patient can progress to a higher weight during sessions.
- Walking over obstacles on the ground and direction change with use of cones.
- Functional activities like transfer exercise (stand/sit exercise) and squatting The
monitoring of the exercise, its progress and any other observation will be register in
a control form by the physiotherapist.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04079803 -
PTI-125 for Mild-to-moderate Alzheimer's Disease Patients
|
Phase 2 | |
| Completed |
NCT04044495 -
Sleep, Rhythms and Risk of Alzheimer's Disease
|
N/A | |
| Terminated |
NCT03052712 -
Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies
|
N/A | |
| Recruiting |
NCT04520698 -
Utilizing Palliative Leaders In Facilities to Transform Care for Alzheimer's Disease
|
N/A | |
| Active, not recruiting |
NCT04606420 -
Can Lifestyle Changes Reverse Early-Stage Alzheimer's Disease
|
N/A | |
| Recruiting |
NCT05820919 -
Enhancing Sleep Quality for Nursing Home Residents With Dementia - R33 Phase
|
N/A | |
| Terminated |
NCT03672474 -
REGEnLIFE RGn530 - Feasibility Pilot
|
N/A | |
| Completed |
NCT03430648 -
Is Tau Protein Linked to Mobility Function?
|
||
| Recruiting |
NCT04522739 -
Spironolactone Safety in African Americans With Mild Cognitive Impairment and Early Alzheimer's Disease
|
Phase 4 | |
| Recruiting |
NCT05557409 -
A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease Agitation
|
Phase 3 | |
| Recruiting |
NCT05288842 -
Tanycytes in Alzheimer's Disease and Frontotemporal Dementia
|
||
| Recruiting |
NCT04949750 -
Efficacy of Paper-based Cognitive Training in Vietnamese Patients With Early Alzheimer's Disease
|
N/A | |
| Completed |
NCT06194552 -
A Multiple Dose Study of the Safety and Pharmacokinetics of NTRX-07
|
Phase 1 | |
| Completed |
NCT03239561 -
Evaluation of Tau Protein in the Brain of Participants With Alzheimer's Disease Compared to Healthy Participants
|
Early Phase 1 | |
| Completed |
NCT03184467 -
Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Alzheimer Patients
|
Phase 2 | |
| Active, not recruiting |
NCT03676881 -
Longitudinal Validation of a Computerized Cognitive Battery (Cognigram) in the Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease
|
||
| Terminated |
NCT03487380 -
Taxonomic and Functional Composition of the Intestinal Microbiome: a Predictor of Rapid Cognitive Decline in Patients With Alzheimer's Disease
|
N/A | |
| Completed |
NCT05538455 -
Investigating ProCare4Life Impact on Quality of Life of Elderly Subjects With Neurodegenerative Diseases
|
N/A | |
| Recruiting |
NCT05328115 -
A Study on the Safety, Tolerability and Immunogenicity of ALZ-101 in Participants With Early Alzheimer's Disease
|
Phase 1 | |
| Completed |
NCT05562583 -
SAGE-LEAF: Reducing Burden in Alzheimer's Disease Caregivers Through Positive Emotion Regulation and Virtual Support
|
N/A |